MétaCan
Menu
Retour à la cohorte
Enregistrement W2024486592 · doi:10.4103/1673-5374.155422

Prazosin: a potential new management tool for iatrogenic autonomic dysreflexia in individuals with spinal cord injury?

2015· article· en· W2024486592 sur OpenAlex
AaronA Phillips, MeiM.Z. Zheng, StacyL Elliott, AndreiV Krassioukov

Pourquoi ce travail est dans la base

Une base qui oublie comment elle a trouvé un travail ne peut pas être vérifiée. Voici les voies qui ont admis celui-ci.

affAu moins un auteur déclare une institution canadienne dans l'instantané OpenAlex épinglé.
aboutLe titre ou le résumé porte un signal canadien du lexique géographique.

Notice bibliographique

RevueNeural Regeneration Research · 2015
Typearticle
Langueen
DomaineMedicine
ThématiqueSpinal Cord Injury Research
Établissements canadiensGF Strong Rehabilitation CentreUniversity of British Columbia, Okanagan CampusUniversity of British ColumbiaInternational Collaboration On Repair DiscoveriesVancouver Coastal Health
Organismes subventionnairesnon disponible
Mots-clésAutonomic dysreflexiaMedicineSpinal cord injuryNifedipineAnesthesiaGabapentinPrazosinPopulationBlood pressureInternal medicineSpinal cord

Résumé

récupéré en direct d'OpenAlex

Spinal cord injury (SCI) is a devastating condition that not only results in a loss of motor functions but also severe autonomic dysfunctions (Krassioukov and Claydon, 2006). Autonomic dysreflexia (AD) is a life threatening episode of transient hypertension that occurs up to 30x/day (11x/day on average) in those with cervical or high thoracic SCI (Hubli et al., 2015). Most common triggers of AD are from stimuli such as a full bowel and/or bladder, or sexual arousal (Teasell et al., 2000). Penile vibrostimulation (PVS) is a clinical procedure for sperm retrieval used for the purpose of family planning or fertility assessment that unfortunately iatrogenically induces episodes of AD (Elliott, 2006). Recently, we published a clinical trial highlighting that prazosin may be a viable option for treating AD secondary to PVS (Phillips et al., 2014). Currently, the most commonly used medication to mitigate the severity of AD episodes during PVS is nifedipine (Adalat), an immediate-release calcium channel blocker (Krassioukov et al., 2009). However, individuals with SCI experience persistently low resting blood pressure (BP) as well as orthostatic hypotension (Krassioukov and Claydon, 2006). While nifedipine is effective at significantly reducing the severity of BP increases secondary to AD, it unfortunately has the tendency tolower resting BP for up to 5 hours. Also, SCI patients with persistent hypotension may experience dizziness, fatigue, and weakness after being administered nifedipine (Krassioukov et al., 2009). Together, these factors contribute to the need to explore alternative therapies for mitigating AD severity in the SCI population. Nifedipine lowers BP by blocking both the renin-angiotension (RAS) pathway and the α-adrenergic receptors. Prazosin (Minipress), on the other hand, is a selective α-adrenergic blocker that preserves the vasoactive actions of the RAS pathways (Jaillon, 1980; Krassioukov and Claydon, 2006). Consequently, prazosin exudes a less abrupt suppressive effect on resting BP (Jaillon, 1980). A previous clinical study suggests that prazosin may be a feasible prophylactic treatment of AD, as it has shown a reduced incidence and severity of AD episodes in hospitalized SCI patients due to urogenic complications or other causes (Krum et al., 1992). We recently conducted a clinical trial to examine the efficacy of prazosin at reducing AD severity in SCI outpatients undergoing PVS who regularly experienced severe iatrogenically-induced episodes of AD. Six patients with complete chronic SCI (> 2 years) were tested in a placebo controlled trial using a 1 mg tablet of prazosin at home the night before testing (loading dose), followed by a second 1 mg tablet 2 hours prior to the PVS procedure. Participants acted as their own controls. Hemodynamic assessments took place for 10 minutes prior to and during the procedure. The resting BP was calculated from minutes 3–8 of the 10 minute recording before the procedure, after both doses of prazosin were administered. All six participants experienced AD episodes following ejaculation from PVS after taking either placebo or prazosin. We noted two major findings: 1) patients experienced a significantly smaller increase in SBP after ejaculation after being administered prazosin compared to placebo (97 ± 34 mmHg vs. 141 ± 46 mmHg, P = 0.02), 2) no difference in resting BP between prazosin and placebo trials (Figure 1). The results suggest that like nifedipine, prazosin is effective at reducing the severity of iatrogenically-induced AD due to PVS. However, prazosin did not result in a decrease in resting BP, suggesting it may be a viable alternative for mitigating AD severity, with particular benefit in patients suffering from persistent hypotension.Figure 1: Comparing systolic blood pressure (SBP), diastolic blood pressure (DBP), and mean arterial pressure (MAP) at baseline (figure on left) to development of autonomic dysreflexia during ejaculation with penile vibrostimulation (figure on right), after either placebo or prazosin was administered.The increase in SBP was mitigated during ejaculation when prazosin was administered compared to placebo (*P = 0.02), as shown with two-way repeated measures ANOVA; however, resting blood pressure was not different between the two trials.One critical consideration when administering prazosin to manage AD symptoms in SCI is the risk of eliciting what is referred to as a “first-dose phenomenon”; where patients experience a severe drop in BP the first time it is administered (Graham et al., 1976). It is recommended that if administering as prophylactic, the first dose (i.e., “loading dose”) should be ingested before night-time sleep (when patient is in supine position) to mitigate the risk of severe orthostatic hypotension. This phenomenon does not occur on subsequent days of administration. Larger clinical trials should be conducted in the future, using more sophisticated BP measurements (i.e., 15 minute interval 24 hour ambulatory BP monitoring), to further establish the use of prazosin as a prophylactic management of AD. This would allow for more powerful and generalizable results. In conclusion, we have shown for the first time that 1 mg prazosin (administered orally once the night before, and once 2 hours prior to ejaculation) is effective at reducing the severity of iatrogenically-induced AD in those with SCI during PVS. Importantly, low resting BP was not exacerbated by prazosin in SCI patients. AAP is supported by the Heart and Stroke Foundation of Canada, and the Michael Smith Foundation for Health Research. AVK is supported by the Paralyzed Veterans of America, the Craig Neilson Foundation, the Canadian Institute of Health Research, and the Heart and Stroke Foundation of Canada. We would like to thank the editors of Neural Regeneration Research for their invitation to editorialize our findings.

Récupéré en direct depuis OpenAlex et désinversé. Les résumés ne sont pas conservés dans cette base de données : les index inversés représentent 8,6 Go des 9,3 Go de texte de la base, et le serveur dispose de 13 Go libres.

Prédiction distillée sur la base complète

Imitation des enseignants

Ni prévalence calibrée, ni vérité terrain. Validation humaine à venir. Apprise à partir de 10 348 étiquettes directes de Codex et de 10 348 étiquettes directes de Gemma. Le mode candidate est l'union des têtes enseignantes seuillées; le consensus est leur intersection. Ces sorties portent le statut machine_predicted_unvalidated et ne sont ni des étiquettes humaines ni des étiquettes directes de modèles de pointe.

score de la tête « metaresearch » (Codex)0,002
score de la tête « metaresearch » (Gemma)0,000
Version: codex-gemma-dda1882f352aStatut de validation: machine_predicted_unvalidated
Catégories candidatesaucune
Catégories consensuellesaucune
DomaineSignal candidat: aucune · Signal consensuel: aucune
Devis d'étudeSignal candidat: Sans objet · Signal consensuel: aucune
GenreSignal candidat: Empirique · Signal consensuel: Empirique
Score de désaccord entre enseignants0,382
Score d'incertitude au seuil0,789

Scores Codex et Gemma par catégorie

CatégorieCodexGemma
Métarecherche0,0020,000
Méta-épidémiologie (sens strict)0,0000,000
Méta-épidémiologie (sens large)0,0000,000
Bibliométrie0,0010,001
Études des sciences et des technologies0,0000,000
Communication savante0,0000,000
Science ouverte0,0000,000
Intégrité de la recherche0,0000,001
Charge utile insuffisante (le modèle a refusé de juger)0,0000,000

Scores machine (provisoires)

Les deux têtes enseignantes du modèle étudiant, lues sur ce travail. Un score ordonne la base pour la relecture; il n'affirme jamais une catégorie, et le statut de validation accompagne chaque rangée tel quel.

Scores de référence d'un modèle non mature (critères de maturité non atteints, 7 itérations). Un score ordonne; il n'affirme jamais une catégorie.

Tête enseignante Opus0,172
Tête enseignante GPT0,473
Écart entre enseignants0,301 · la distance entre les deux têtes enseignantes sur ce seul travail
Statut de validationscore_only:v0-immature-baseline · tel quel depuis la passe de notation : score_only signifie que le nombre peut ordonner les travaux, et qu'aucune étiquette de catégorie n'en découle